Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden proposes Medicaid, Medicare cover ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

It's uncertain whether the Biden administration proposal to cover obesity drugs in Medicare and Medicaid will survive ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...

Ozempic, Wegovy, and other weight-loss drugs could make millions healthier, but access and affordability barriers abound.

Recent data from an Amgen obesity-drug trial only reinforced investors' impressions that Eli Lilly and Novo Nordisk have a prohibitive head start, thanks, in particular, to a new generation of Lilly ...

A new study finds people who take weight-loss drugs also cut back on alcohol consumption. Researchers think the drugs could ...